BPBijay Pattnaik

Bijay Pattnaik

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bijay Pattnaik has a total of 43 co-authors. Here are the top co-authors by number of shared publications:

  • Anurag Agrawal

    Trivedi School of Biosciences, Ashoka University, Sonepat, Haryana, India, Sonepath, Haryana, 131029, INDIA

    4 shared publications
  • Randeep Guleria

    Pulmonary, Critical Care & Sleep Medicine, All India Institute of Medical Sciences, Room no-9, Porta cabin, New Private Ward, Dept of Pulmonary, Critical Care & Sleep Medicine, AIIMS, New Delhi, India, 110029, New Delhi, 110029, INDIA

    4 shared publications
  • Saurabh Mittal

    Pulmonary, Critical Care & Sleep Medicine, All India Institute of Medical Sciences, Room no-9, Porta cabin, New Private Ward, Dept of Pulmonary, Critical Care & Sleep Medicine, AIIMS, New Delhi, India, 110029, New Delhi, Delhi, 110029, INDIA

    4 shared publications
  • Vijay Hadda

    Pulmonary, Critical Care & Sleep Medicine, All India Institute of Medical Sciences, Room no-9, Porta cabin, New Private Ward, Dept of Pulmonary, Critical Care & Sleep Medicine, AIIMS, New Delhi, India, 110029, New Delhi, 110029, INDIA

    4 shared publications
  • Divyanjali Rai

    Pulmonary, Critical Care & Sleep Medicine, All India Institute of Medical Sciences, Room no-9, Porta cabin, New Private Ward, Dept of Pulmonary, Critical Care & Sleep Medicine, AIIMS, New Delhi, India, 110029, New Delhi, 110029, INDIA

    3 shared publications
  • Geetika Yadav

    Division of Non-Communicable Disease, Indian Council of Medical Research, V. Ramalingaswami Bhawan, P.O. Box No. 4911 Ansari Nagar, New Delhi - 110029, New Delhi, Delhi, 110029, INDIA

    3 shared publications

Latest Publications

  • MicroRNA expression in exhaled breath condensate differentiates between asthma and chronic obstructive pulmonary disease

    by Bijay Pattnaik, Sunil Bangaru, Divyanjali Rai, Jaya Tak, Naveen Bhatraju, Seetu Kashyap, Jyoti Kumari, Umashankar Verma, Geetika Yadav, R S Dhaliwal, et al.

    Asthma and chronic obstructive pulmonary disease (COPD) have many common clinical characteristics, thus making reliable differentiation between these two challenging. The goal of this study is to determine the clinical value of exhaled breath condensate (EBC) derived miRNAs to discriminate between asthma and COPD. This cross-sectional study included 65 subjects each with asthma (mean/SD age: 39/13 years, Male n/%: 27/42%), COPD (mean/SD age: 61/9 years, Male n/%: 53/81%) and healthy controls (mean/SD age: 34.4/12 years, Male n/%: 50/77%). EBC was collected using R-tubes and 40 EBC samples from each group were used for miRNA profiling. Profiling data was curated and the most highly expressed miRNAs were shortlisted for further validation. Selected microRNAs were subsequently validated using quantitative-PCR in an independent set of 25 subjects from both disease groups. A total of 103 miRNAs were significantly upregulated in the EBC of asthma patients and 97 miRNAs were upregulated in the EBC of COPD patients compared to control group. However, miR-512-3p was downregulated and miR-517c was upregulated in COPD compared with asthma. The top unique miRNAs were shortlisted for further validation. Of these, miR-375 was upregulated in asthma, while miR-297, miR-367 and miR-539 were upregulated in COPD compared with healthy controls. Further, miR-512-3p was down-regulated and miR-517c was upregulated in COPD compared with asthma. The comparison exhibited excellent discriminatory power with 100% differential expression of miR-512-3p and miR-517c secreted by respiratory cells, they could be quantitated in EBC samples and used to differentiate between asthma and COPD.


  • Open Access

    Utility of microRNA analysis in exhaled breath condensate of sarcoidosis and mediastinal tuberculosis patients: a pilot study

    by Bijay Pattnaik, Sryma Pb, Naveen Bhatraju, Saurabh Mittal, Sudheer Arava, Deepali Jain, Baibaswata Nayak, Pavan Tiwari, Vijay Hadda, Anant Mohan, et al.

    Background: Sarcoidosis and tuberculosis (TB) are the two most common causes of granulomatous mediastinal lymphadenopathy. These often exhibit overlapping clinical and radiological characteristics, rendering accurate diagnosis difficult. MicroRNA (miRNA) analysis is increasingly utilised as a potential biomarker for various diseases. Exhaled breath condensate (EBC) is a noninvasive technique for biomarker evaluation in different respiratory conditions. We attempted to identify differentially expressed miRNAs in the EBC of sarcoidosis and mediastinal TB patients.Methods: EBC was obtained from subjects with a definitive diagnosis of sarcoidosis and mediastinal TB. EBC was also obtained from age- and sex-matched control subjects. From EBC, miRNA isolation, cDNA preparation and qPCR array were performed. Differentially expressed miRNAs were shortlisted. Further validation was conducted in the EBC of a new subset.Results: Subjects with a definitive diagnosis of sarcoidosis (50) and TB (50), and control subjects (50) were included. qPCR array from EBC (20 subjects from each group) shortlisted eight differentially expressed miRNAs (miR-126, miR-132, miR-139-3p, miR-139-5p, miR-181c, miR-454, miR-512-3p and miR-362-5p). In the validation set (EBC of 30 subjects from each group), miR-126 and miR-132 were differentially expressed significantly. The miR-126 and miR-132 expression ratio could differentiate sarcoidosis from mediastinal TB with an AUC of 0.618 (82% specificity and 41% sensitivity).Conclusion: While EBC miRNA expression is significantly and differently altered in sarcoidosis and mediastinal TB, a simple ratiometric approach failed to provide clinically useful signatures for differentiating between the two in patients with mediastinal lymphadenopathy.


  • Open Access

    Dual Detection of Hepatitis B and C Viruses Using CRISPR‐Cas Systems and Lateral Flow Assay

    by Syeda Najidah Shahni, Sarah Albogami, Iqbal Azmi, Bijay Pattnaik, Rituparna Chaudhuri, Kapil Dev, Jawed Iqbal, Amit Sharma, Tanveer Ahmad

    The development of sensitive and specific diagnostic tools for hepatitis B virus (HBV) and hepatitis C virus (HCV) remains crucial for effective disease management and control. In this study, we utilized CRISPR‐Cas12 and CRISPR‐Cas13 systems for the detection of HBV (DNA virus) and HCV (RNA virus), respectively. We designed and tested multiple guide RNAs (gRNAs) targeting both viruses, confirming successful cleavage of target sequences through gel electrophoresis and a fluorescent reporter assay. Using optimized gRNAs, we developed a lateral flow assay (LFA) for sensitive detection of HBV and HCV, demonstrating a concentration‐dependent signal increase. Importantly, no cross‐reactivity was observed with other viral targets. To further enhance sensitivity, we employed a dual‐enzyme approach, combining Cas12 and Cas13 in a single reaction, which significantly improved detection limits for both viruses. Finally, we developed a dual antigen detection LFA strip capable of simultaneously detecting both HBV and HCV in a single sample. This approach holds promise for point‐of‐care (POC) diagnostics where the specific viral infection is unknown. This study addresses the current limitations in CRISPR‐Cas based diagnostics, namely, the need for ultrasensitive detection methods and the ability to detect multiple antigens using a single test strip. Our findings demonstrate the feasibility of using CRISPR‐Cas systems for highly sensitive and specific detection of HBV and HCV, paving the way for potential POC application.


  • Open Access

    microRNAs in exhaled breath condensate for diagnosis of lung cancer in a resource-limited setting: a concise review

    by Divyanjali Rai, Bijay Pattnaik, Sunil Bangaru, Jaya Tak, Jyoti Kumari, Umashankar Verma, Rohit Vadala, Geetika Yadav, Rupinder Singh Dhaliwal, Sunil Kumar, et al.

    Lung cancer is one of the common cancers globally with high mortality and poor prognosis. Most cases of lung cancer are diagnosed at an advanced stage due to limited diagnostic resources. Screening modalities, such as sputum cytology and annual chest radiographs, have not proved sensitive enough to impact mortality. In recent years, annual low-dose computed tomography has emerged as a potential screening tool for early lung cancer detection, but it may not be a feasible option for developing countries. In this context, exhaled breath condensate (EBC) analysis has been evaluated recently as a noninvasive tool for lung cancer diagnosis. The breath biomarkers also have the advantage of differentiating various types and stages of lung cancer. Recent studies have focused more on microRNAs (miRNAs) as they play a key role in tumourigenesis by regulating the cell cycle, metastasis and angiogenesis. In this review, we have consolidated the current published literature suggesting the utility of miRNAs in EBC for the detection of lung cancer.


  • Open Access

    A review on electronic nose for diagnosis and monitoring treatment response in lung cancer

    by Rohit Vadala, Bijay Pattnaik, Sunil Bangaru, Divyanjali Rai, Jaya Tak, Seetu Kashyap, Umashankar Verma, Geetika Yadav, Rs Dhaliwal, Saurabh Mittal, et al.

    Lung cancer is one of the common malignancies with high mortality rate and a poor prognosis. Most lung cancer cases are diagnosed at an advanced stage either due to limited resources of infrastructure, trained human resources, or delay in clinical suspicion. Low-dose computed tomography has emerged as a screening tool for lung cancer detection but this may not be a feasible option for most developing countries. Electronic nose is a unique non-invasive device that has been developed for lung cancer diagnosis and monitoring response by exhaled breath analysis of volatile organic compounds. The breath-print have been shown to differ not only among lung cancer and other respiratory diseases, but also between various types of lung cancer. Hence, we postulate that the breath-print analysis by electronic nose could be a potential biomarker for the early detection of lung cancer along with monitoring treatment response in a resource-limited setting. In this review, we have consolidated the current published literature suggesting the use of an electronic nose in the diagnosis and monitoring treatment response of lung cancer.